Treatment Guidelines - 2017
January 1, 2014 (Issue 137)
- Drugs for Lipids
Superseded by The Medical Letter "Lipid-Lowering Drugs" - Issue 1506, October 24, 2016
HMG-CoA reductase inhibitors (statins) inhibit the enzyme that catalyzes the rate-limiting step in cholesterol synthesis. The subsequent reduction in hepatic cholesterol leads to increased expression of LDL receptors, which in turn increases...
February 1, 2014 (Issue 138)
- Drugs for HIV Infection
Antiretroviral therapy is recommended for all HIV-infected patients, both to reduce the risk of disease progression and to prevent transmission of the virus to others. Various guidelines for treatment of HIV infection are...
March 1, 2014 (Issue 139)
- Drugs for Type 2 Diabetes
Superseded by The Medical Letter "Drugs for Type 2 Diabetes" - Issue 1512, January 16, 2017
The goal of drug therapy for type 2 diabetes is to achieve and maintain a near-normal A1C concentration without inducing hypoglycemia; the target is generally an A1C of <7.0%. Treating to this target has been shown to prevent the...
April 1, 2014 (Issue 140)
- Drugs for Peptic Ulcer Disease and GERD
H2-RECEPTOR ANTAGONISTS (H2RAs) — Currently available H2RAs are listed in Table 1. These drugs inhibit the action of histamine at the H2-receptor of the gastric parietal cell, decreasing basal acid secretion and, to a lesser degree, food-stimulated acid secretion. All H2RAs are about equally effective for treatment of PUD and GERD. H2RAs are faster acting than PPIs...
May 1, 2014 (Issue 141)
- Drugs for Hypertension
Most recent guidelines recommend a BP goal of 140/90 mm Hg. For patients ≥60 years old without diabetes or chronic kidney disease, one guideline recommends 150/90 mm Hg both as the drug treatment initiation threshold and treatment target; this higher target is controversial, except in patients ≥80 years...
June 1, 2014 (Issue 142)
- Adult Immunization
Vaccines recommended for adults residing in the US are reviewed here. Vaccines for travel have been reviewed separately.
Eight vaccines are currently recommended by the US Advisory Committee on Immunization Practices (ACIP) for routine use in adults at various...